Sarcopenia therapeutics currently exhibits a growing pipeline with 13 drug candidates, P&S Market Research.
Sarcopenia Therapeutics Pipeline in 2018
The study analyzed that the sarcopenia therapeutics pipeline comprises of 13 drug candidates in different stages of development. Further, the analysis also states that the pipeline has around 15% of the drug candidates that are being developed as gene therapy.
Browse report overview with detailed TOC on "Sarcopenia Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.psmarketresearch.com/market-analysis/sarcopenia-therapeutics-pipeline-analysis
Insights on Pipeline Segments
Novartis AG, and Regeneron Pharmaceuticals Inc., have one drug candidate each in the Phase II stage of development for the treatment of the disease. In December 2017, Biophytis SAS announced that the Federal Agency for Medicines and Health Products (FAMHP) approved to conduct the SARA-INT Phase II interventional study of sarcopenia in Belgium.
Sarcopenia therapeutics Pipeline Marked by Positive Clinical Trials Results
The drugs being developed by the various pharmaceutical companies for the treatment of sarcopenia have demonstrated positive clinical trial results which in-turn aids in their further development. For instance, In June 2017, Novartis AG announced the positive results of a 24-week randomized, double-blind, placebo-controlled, parallel-arm, proof-of-concept study of bimagrumab on skeletal muscle mass and function in older adults with sarcopenia and mobility limitations. In February 2016, ATA 842 demonstrated increased muscle mass and muscle strength in the treatment of young and old mice in four weeks.
Rise in Patent Approvals for Sarcopenia Therapeutics Expected to Provide Collaborative Opportunities to the Pharmaceutical Companies
It has been observed that most of the drug candidates have received or have filed for patent covering a novel mechanism for the treatment of sarcopenia. For instance, in June 2016, Novartis AG received patent for the invention related to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of age-related sarcopenia (WO2015IB59369 20151204). Patent approval helps in increasing opportunities for invention improvement and uniqueness for the pharmaceutical companies.
Some of the key players developing drugs for the treatment of sarcopenia include Novartis AG, Biophytis SAS and Vibe Pharmaceuticals LLC.
Sarcopenia Therapeutics Pipeline Analysis